Literature DB >> 11558711

Public attitudes about genetic testing for Alzheimer's disease.

P J Neumann1, J K Hammitt, C Mueller, H M Fillit, J Hill, N A Tetteh, K S Kosik.   

Abstract

In a general population survey (N = 314), 79 percent of respondents stated that they would take a hypothetical genetic test to predict whether they will eventually develop Alzheimer's disease. The proportion fell to 45 percent for a "partially predictive" test (which had a one in ten chance of being incorrect). Inclination to obtain testing was similar across age groups. Respondents were willing to pay $324 for the completely predictive test. Respondents stated that if they tested positive, they would sign advance directives (84 percent), get their finances in order (74 percent), and purchase long-term care insurance (69 percent). Only a third of respondents expressed concern about confidentiality. The results suggest that people value genetic testingfor personal and financial reasons, but they also underscore the need to counsel potential recipients carefully about the accuracy and implications of test information.

Entities:  

Keywords:  Empirical Approach; Genetics and Reproduction

Mesh:

Year:  2001        PMID: 11558711     DOI: 10.1377/hlthaff.20.5.252

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  32 in total

1.  Consumer preferences for the predictive genetic test for Alzheimer disease.

Authors:  Ming-Yi Huang; Sally A Huston; Matthew Perri
Journal:  J Genet Couns       Date:  2013-07-12       Impact factor: 2.537

2.  Differences between African American and White research volunteers in their attitudes, beliefs and knowledge regarding genetic testing for Alzheimer's disease.

Authors:  Ibidapo Akinleye; J Scott Roberts; Charmaine D M Royal; Erin Linnenbringer; Thomas O Obisesan; Grace-Ann Fasaye; Robert C Green
Journal:  J Genet Couns       Date:  2011-06-09       Impact factor: 2.537

3.  Disclosing the disclosure: factors associated with communicating the results of genetic susceptibility testing for Alzheimer's disease.

Authors:  Sato Ashida; Laura M Koehly; J Scott Roberts; Clara A Chen; Susan Hiraki; Robert C Green
Journal:  J Health Commun       Date:  2009-12

Review 4.  Personal utility in genomic testing: a systematic literature review.

Authors:  Jennefer N Kohler; Erin Turbitt; Barbara B Biesecker
Journal:  Eur J Hum Genet       Date:  2017-03-15       Impact factor: 4.246

5.  Public beliefs and knowledge about risk and protective factors for Alzheimer's disease.

Authors:  J Scott Roberts; Sara J McLaughlin; Cathleen M Connell
Journal:  Alzheimers Dement       Date:  2014-03-14       Impact factor: 21.566

Review 6.  Emerging issues in public health genomics.

Authors:  Dana Dolinoy; Beth Tarini; J Scott Roberts
Journal:  Annu Rev Genomics Hum Genet       Date:  2014       Impact factor: 8.929

7.  Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials.

Authors:  Joshua D Grill; Yan Zhou; David Elashoff; Jason Karlawish
Journal:  Neurobiol Aging       Date:  2015-11-22       Impact factor: 4.673

8.  Rural stakeholder perceptions about cognitive screening.

Authors:  Lisa Kirk Wiese; James E Galvin; Christine L Williams
Journal:  Aging Ment Health       Date:  2018-12-27       Impact factor: 3.658

Review 9.  Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues.

Authors:  J Scott Roberts; Wendy R Uhlmann
Journal:  Prog Neurobiol       Date:  2013-04-09       Impact factor: 11.685

10.  Disclosure of APOE genotype for risk of Alzheimer's disease.

Authors:  Robert C Green; J Scott Roberts; L Adrienne Cupples; Norman R Relkin; Peter J Whitehouse; Tamsen Brown; Susan LaRusse Eckert; Melissa Butson; A Dessa Sadovnick; Kimberly A Quaid; Clara Chen; Robert Cook-Deegan; Lindsay A Farrer
Journal:  N Engl J Med       Date:  2009-07-16       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.